Search

An international research team has discovered the key protein in an enzyme responsible for lengthening the ends of chromosomes, a surprising finding that potentially could lead to the development of [...]

An international research team has discovered the key protein in an enzyme responsible for lengthening the ends of chromosomes, a surprising finding that potentially could lead to the development of [...]

TITLE: EFFECTIVENESS OF VIRAL STIMULATORS ON THE RELEASE OF REVERSE TRANSCRIPTASE FROM MONOCYTES OF PATIENTS WITH BREAST CANCER AUTHORS: A.M. Al-Sumidaie, S.J. Leinster, C.D. Green and C.A. Hart. University of [...]

SOURCE: Proceedings of the National Academy of Sciences, August 15, 1992;89(16) A California research team reports evidence of retrovirus-like particles and reverse transcriptase activity in an HIV-negative 66-year-old woman with [...]

The identification of the fifth known mutation giving HIV-1 resistance to zidovudine (AZT) makes it likely that the most common mutations conferring AZT resistance are now known, a British/Dutch study [...]

According to an abstract submitted by the authors to the joint meeting of the American Society for Biochemistry and Molecular Biology/Biophysical Society, held in Houston, Texas, "We have studied the [...]

AUTHORS: D.A Matthews, Z. Hostomska, Z. Hostomsky and J. Davies. Agouron Pharmaceuticals, La Jolla, California. According to an abstract submitted by the authors to the joint meeting of the American [...]

AUTHORS: A. Bacolla, G.L. Hansen, J.M. Rose, C.-K. Shih and J.A. Griffin. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut. According to an abstract submitted by the authors to the joint meeting [...]

Merck & Co. (Rahway, NJ) and Boehringer Ingelheim (Ridgefield, CT) have both suspended single agent clinical trials with their non-nucleoside, TIBO-like anti-HIV reverse transcriptase (RT) inhibitors due to the rapid [...]

SOURCE: Journal of Virology, September 1991;4887-4892. Laboratory strains of HIV-1 can develop resistance to the newly developed non-nucleoside reverse transcriptase (RT) inhibitors, and resistance to one of these inhibitors confers [...]

SOURCE: The Journal of Medicinal Chemistry, July 1991;34(7):2231-2241. The structure-activity relationships of the non -nucleoside HIV-1 reverse transcriptase (RT) inhibitor known as BI-RG-587 (nevirapine) and related compounds are described by [...]

According to the authors' abstract of an article published in Virology, "The initiation of HIV-1 reverse transcription is primed by a cellular tRNA(Lys,3) molecule which is bound to a complementary [...]

AUTHORS: R.A. Gibbs and M.A. Ansari-Lari. Baylor University, College of Medicine, Institute for Molecular Genetics, Houston, Texas. According to an abstract submitted by the authors to the Keystone Symposia titled [...]

Yale University The mutation at amino acid 90 of human immunodeficiency virus type 1 reverse transcriptase (HIV -1 RT) can cause cross-resistance to antiviral nucleoside triphosphate analogs and phosphonoformate, according [...]

According to an abstract submitted by the authors to the Conference on Chemicals, Mutations and Cancer, held December 12, 1992, in Banff, Alberta, Canada, "The unusually high mutation frequency exhibited [...]

SOURCE: Virology, June 1992;188(2):900-904. A mutation in either of two specific amino acids in the HIV-1 reverse transcriptase (RT) gene makes the virus resistant to TIBO derivatives and other non-nucleoside [...]

AUTHORS: R.A. Halpin, L.A. Geer, D.W. Wyatt, K.P. Vyas, M. Hichens and S. Vickers. Merck Sharp & Dohme Research Laboratories, Department of Drug Metabolism, West Point, Pennsylvania. According to an [...]

AUTHORS: S.K. Balani, S.M. Pitzenberger, L.R. Kauffman, B.H. Arison, H.G. Ramjit, M.E. Goldman, J.A. O'Brien, J.M. Hoffman and A.D. Theoharides. Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania. According [...]

AUTHORS: T.S. Heard and L.K. Moen. Department of Chemistry and Biochemistry, Old Dominion University, Norfolk, Virginia. According to an abstract submitted by the authors to the joint meeting of the [...]

AUTHORS: W.A. Beard. A. Kumar and S.H. Wilson. Laboratory of Biochemistry, U.S. National Cancer Institute, U.S. National Institutes of Health, Bethesda, Maryland. According to an abstract submitted by the authors [...]

AUTHORS: R.H. Ingraham, J.C. Wu, J. Hopkins, D.E.H. Palladino, R.M. House, K.A. Cohen, J. Adams, P.R. Farina and Peter M. Grob. Boehringer Ingelheim Pharmaceuticals lnc., Ridgefield, Connecticut. According to an [...]

AUTHORS: G.F. Clark, S.C. Oehninger and L.K. Moen. Department of Biochemistry and the Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia, and the Department of Chemistry and [...]

AUTHORS: S.H. Wilson, A. Kumar, P. Becerra, B.J. Lee and D. Hatfield. Laboratory of Biochemistry and Experimental Carcinogenesis, U.S. National Cancer Institute, U.S. National Institutes of Health, Bethesda, Maryland. According [...]

AUTHORS: T.A. Steitz, L. Kohlstaedt, J. Wang, J. Friedman, P. Rice and L. Beese. Department of Molecular Biophysics and Biochemistry, Howard Hughes Medical Institute, Yale University, New Haven, Connecticut. According [...]

AUTHORS: N. Santoro and D.J. Hupe. Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan. According to an abstract submitted by the authors to the joint meeting of the American [...]

AUTHORS: D.B. Evans, K. Brawn, M.R. Deibel Jr., W.G. Tarpley and S.K. Sharma. The Upjohn Company Upjohn Laboratories, Kalamazoo Michigan. According to an abstract submitted by the authors to the [...]

AUTHORS: R.H. Ingraham, J.C. Wu, J. Hopkins, D.E.H. Palladino, R.M. House, K.A. Cohen, J. Adams, P.R. Farina and P.M. Grob. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut. According to an abstract [...]

AUTHORS: G.F. Clark(1), S.C. Oehninger(2) and L.K. Moen(3). (1) Department of Biochemistry and (2) Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia, and (3) Department of Chemistry [...]

AUTHORS: A. Bacolla, G.L. Hansen, J.M. Rose, C.-K. Shih and J.A. Griffin. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut. According to an abstract submitted by the authors to the joint meeting [...]

SOURCE: Journal of Biological Chemistry, December 15, 1991;266(35):23529-23536. Compounds derived from ipecac inhibit HIV-1 reverse transcriptase (RT), University of Illinois pharmacists report. Ipecac is derived from the dried roots and [...]

Texas Future AIDS drugs might assist or out-perform AZT -the currently preferred medication - by crippling the same target molecule in the virus, according to a researcher at the University [...]

SOURCE: Science, September 27, 1991; 253(5027):1557 -1559. Mutations in HIV isolates that confer resistance to ddI restore AZT sensitivity to previously AZT-resistant strains of the virus, Burroughs Wellcome researchers report. [...]

SOURCE: Proceedings of the National Academies of Science, June 15, 1991;88(12):5262-5266. HIV-1 apparently has not one, but two functional reverse transcriptases, Swiss researchers report. Peter Hafkemeyer and colleagues of the [...]

AUTHORS: R.W. Sobol, S.H. Wilson, A. Kumar, B.J. Lee, D.L. Hatfield, R. Charubala, W. Pfleiderer and R.J. Suhadolnik. Temple University School of Medicine, Philadelphia; National Cancer Institute, Bethesda, Md.; and [...]